Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Tear Quality" is not a molecule, receptor, or canonical therapeutic target. Instead, it refers to the overall composition and functional integrity of the tear film produced primarily by the lacrimal gland and associated accessory glands. The tear film is a complex mixture of water, ions (such as sodium, potassium, chloride), proteins (including lactoferrin, lysozyme, immunoglobulin A), lipids from meibomian glands, and mucins from goblet cells[1][2][5]. Its main functions are lubricating the ocular surface; protecting against pathogens through antimicrobial proteins; providing nutrients to avascular tissues like the cornea; flushing out debris; and maintaining optical clarity for vision[1][2][5]. Disruption in tear quality can lead to dry eye symptoms or excessive tearing but does not represent a single molecular entity that can be directly targeted by drugs[3][5]. Therefore, "Tear Quality" should not be classified as a molecular target such as an enzyme or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tear Quality.